Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Pathol. 2022 Oct 14;258(4):325–338. doi: 10.1002/path.6006

Table 4.

Multivariable analysis of GDA expression in clear cell ovarian carcinoma

# of events / n Comparison Hazard Ratio (95% CI) LRT P-value

Overall survival 38 / 67
GDA (IHC: h-score) - optimal cut point (clear cell) (reference: <230) >=230 0.53 (0.27–1.05)F 0.0751
Age at surgery 1.03 (0.99–1.07)F 0.0984
Grade (reference: grade 1/2) grade 3 0.25 (0.05–2.47)F 0.3803
Stage (reference: I) II-IV 3.62 (1.69–8.73)F 0.0005
Adjuvant treatment (reference: none) chemo 1.02 (0.24–9.5)F 0.7144

Diseases specific survival 30 / 66
GDA (IHC: h-score) - optimal cut point (clear cell) (reference: <230) >=230 0.44 (0.21–0.92)F 0.0350
Age at surgery 1.01 (0.97–1.05)F 0.5669
Grade reference: grade 1/2) grade 3 0.46 (0.05–61.63)F 0.5288
Stage (reference: I) II-IV 3.72 (1.6–10.11)F 0.0012
Adjuvant treatment (reference: none) chemo 0.97 (0.23–9.06)F 0.7499

Progression-free survival 32 / 37
GDA (IHC: h-score) - optimal cut point (clear cell) (reference: <230) >=230 0.85 (0.33–2.21)F 0.7553
Age at surgery 0.98 (0.94–1.03)F 0.4511
Grade (reference: grade 1/2) grade 3 3 (0.28–412.92)F 0.1419
Stage (reference: I) II-IV 1.86 (0.76–5.43)F 0.1458
Adjuvant treatment (reference: none) chemo 0.87 (0.2–8.22)F 0.8462
F

indicates that the Firth’s penalized maximum likelihood bias reduction method was used to estimate the hazard ratio.